Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here’s a look at the key details from the quarter. Q4 Earnings: Exact Sciences reported ...

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 15.2% in the morning session after the company reported strong first quarter 2025 results which beat analysts' revenue and ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Editor’s note: The headline of this story was updated to correct an error related to the reported day of the week. On Monday, the Centers for Medicare & Medicaid ...